GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...

The market for GSK plc's ( LON:GSK) shares didn't move much after it posted weak earnings recently. We did some digging, and ...

GSK (GSK) continued losses for a seventh straight session as the stock closed xx% lower, at $xx on Friday. The British ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales ...